Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Food Ingredients

Novozymes buys probiotics maker Synergia

by Matt Blois
December 4, 2021 | A version of this story appeared in Volume 99, Issue 44

 

In a move to expand its human health and functional food businesses, the Danish biotechnology firm Novozymes will pay $150 million for a majority stake in India’s Synergia Life Sciences, which makes probiotics and vitamin K2-7. Novozymes expects Synergia to contribute about $23 million in annual sales. In 2020, Novozymes announced deals for the probiotics companies PrecisionBiotics and Microbiome Labs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.